A Million Bottles of Heart Pills Just Got Pulled From Shelves
Amgen just pulled nearly a million bottles of its heart failure drug Corlanor after inspectors found a mystery substance on the tablet coating. With no generic alternative and reports the drug may be discontinued, patients are caught in the crossfire of a massive supply chain failure.
Imagine opening your medicine cabinet, grabbing your daily heart failure pill, and learning that something foreign is stuck to the coating. Not the drug itself, not some toxic chemical (as far as anyone knows), but something that shouldn't be there. Now multiply that scenario by nearly a million bottles.
That's the situation Amgen created when it voluntarily recalled roughly 934,577 bottles of Corlanor, its branded heart failure drug, after quality inspectors found an "unexpected foreign substance" on the exterior coating of tablets from an Italian manufacturing facility. The FDA classified it as a Class II recall, meaning the contamination could cause temporary or reversible health effects, but the odds of serious harm are remote.
No patients have reported injuries. No complaints have been filed. But the sheer scale of this recall tells a story that goes well beyond one mystery speck on a pill.
What's Actually on the Pills?
Nobody's saying. Not Amgen. Not the FDA. The official language describes it only as "unexpected foreign matter" found on the exterior surface of tablets during a reserve sample inspection. Think of it like finding an unidentified smudge on the candy shell of an M&M: the chocolate inside is fine, but you'd still want answers about the shell.
Health hazard assessments concluded that the contamination poses low clinical risk to patients. The foreign material sits on the coating, not inside the tablet core where the active ingredient (ivabradine) lives. Still, "low risk" and "no risk" are very different phrases, and regulators weren't comfortable enough to leave nearly a million bottles in circulation.
The Scope Is Staggering
The recall covers both 5 mg and 7.5 mg Corlanor tablets, with the 5 mg strength packaged in 14-count and 60-count bottles and the 7.5 mg strength in 60-count bottles. These products were distributed across the entire United States between October 2021 and December 2025. Expiration dates on affected lots stretch all the way to , which means some of these bottles would have sat in pharmacies and medicine cabinets for years to come.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
December 2028
The California Board of Pharmacy noted that all lots within expiry processed in a specific packaging area (called AML Building 23) are being recalled. That's not a surgical strike on one bad batch. That's a full evacuation of everything that passed through one part of a factory.
And Corlanor wasn't the only casualty. Around the same time, Amgen also recalled batches of Sensipar (cinacalcet), a kidney disease drug, over foreign substance and manufacturing compliance issues from the same general timeframe. Combined, the two recalls cover at least 944,142 bottles.
The Italy Connection
All the recalled Corlanor tablets were manufactured in Italy at a third-party contract manufacturing facility. Amgen owns plants in Ireland and Singapore, but the Corlanor tablets heading to American patients came from an outsourced partner whose name has never been publicly disclosed.
This is standard practice in pharma. Most big companies rely on contract manufacturers for at least some of their portfolio. It's like a restaurant chain that sources bread from an outside bakery: totally normal, until someone finds something weird in the bread. Then everyone wants to know who's baking it and whether anyone was watching the ovens.
The lack of transparency here is notable. We know the country (Italy), the building area (Building 23), and the scope (massive). We don't know the company name, the city, or what specific quality controls failed. That information lives in non-public regulatory filings and internal audit documents.
A Drug With No Backup Plan
Corlanor isn't just any heart medication. It's prescribed to patients with stable, symptomatic chronic heart failure who have a reduced ejection fraction (meaning their heart isn't pumping blood efficiently enough). These patients take it twice daily, every day, as ongoing maintenance therapy. It's not something you skip for a week while the pharmacy sorts things out.
FDA-approved generic versions of ivabradine are available in the U.S., but when you pull a million bottles of a branded chronic therapy off shelves, you still create real friction for real patients. Pharmacies need to verify lot numbers, source non-recalled stock, and coordinate replacements. For patients who are uninsured or underinsured, those delays can mean gaps in treatment that worsen symptoms or destabilize their condition.
Making things even more complicated: reports indicate that Corlanor has been discontinued by Amgen, with only limited stock remaining in retail distribution. If that's true, this isn't just a temporary supply hiccup. It's the final chapter for a drug that some heart failure patients depend on daily.
The Bigger Picture for Pharma's Supply Chain
Amgen's recall lands at an awkward moment for the pharmaceutical industry. The FDA has been ramping up enforcement on foreign manufacturing sites throughout 2025 and 2026, expanding unannounced inspections and issuing warning letters at the highest rate in five years. On a single day in September 2025, the agency fired off 58 drug-related warning letters.
The problem isn't unique to Italy. Regulators have flagged quality failures at contract manufacturers across Europe and Asia, from unauthorized storage areas at an Italian API facility to data integrity violations at plants in India and China. But the pattern is consistent: when companies outsource production to save costs or scale capacity, quality oversight can slip through the cracks.
The Corlanor recall is a textbook example. A surface-level contamination on a tablet coating sounds minor in isolation. But when it affects nearly a million bottles of a heart failure drug manufactured at an unnamed facility thousands of miles from company headquarters, the "minor" label starts to feel generous.
What Happens Next
For Amgen, this is embarrassing but probably manageable. Corlanor was never a blockbuster revenue driver; it's a niche product in a portfolio dominated by biologics and oncology assets. Wall Street is likely to treat this as a contained operational issue rather than a reason to rethink the investment thesis. The real damage is reputational, especially with the Sensipar recall adding a second data point to the quality narrative.
For patients, the situation is more personal. Amgen says it's working with pharmacies, hospitals, and distributors to facilitate returns and replacements at no additional cost. Patients with questions can contact Amgen Medical Information directly. But if Corlanor is truly being phased out, many of these patients will need their cardiologists to map out an entirely new treatment plan.
And for the industry at large, the lesson is the same one it keeps having to relearn: outsourcing your manufacturing doesn't mean outsourcing your responsibility. When something goes wrong at a contract facility in Italy, it's still your name on the bottle sitting in a patient's medicine cabinet in Ohio.
5 min read
Two CNS Pharma Companies Just Stitched Themselves Together. Here's Why.
Supernus and Indivior are merging into a $2.2 billion CNS and addiction powerhouse, combining ADHD drugs with the dominant opioid treatment franchise. It's specialty pharma's latest bet that brain disorders and addiction belong under one roof.
